Literature DB >> 21965390

Critically ill patients with H1N1 influenza A undergoing extracorporeal membrane oxygenation.

Christopher Bibro, Christine Lasich, Frank Rickman, Nichole E Foley, Sujen K Kunugiyama, Ember Moore, Amy O'Brien, Natalie Sherman, Christine S Schulman.   

Abstract

The most common cause of death due to the H1N1 subtype of influenza A virus (swine flu) in the 2009 to 2010 epidemic was severe acute respiratory failure that persisted despite advanced mechanical ventilation strategies. Extracorporeal membrane oxygenation (ECMO) was used as a salvage therapy for patients refractory to traditional treatment. At Legacy Emanuel Hospital, Portland, Oregon, the epidemic resulted in a critical care staffing crisis. Among the 15 patients with H1N1 influenza A treated with ECMO, 4 patients received the therapy simultaneously. The role of ECMO in supporting patients with severe respiratory failure due to H1N1 influenza is described, followed by discussions of the nursing care challenges for each body system. Variations from standards of care, operational considerations regarding staff workload, institutional burden, and emotional wear and tear of the therapy on patients, patients' family members, and the entire health care team are also addressed. Areas for improvement for providing care of the critically ill patient requiring ECMO are highlighted in the conclusion.

Entities:  

Mesh:

Year:  2011        PMID: 21965390     DOI: 10.4037/ccn2011186

Source DB:  PubMed          Journal:  Crit Care Nurse        ISSN: 0279-5442            Impact factor:   1.708


  2 in total

1.  Ten things that nurses should know about ECMO.

Authors:  Cécile Van Kiersbilck; Elizabeth Gordon; Denise Morris
Journal:  Intensive Care Med       Date:  2016-03-08       Impact factor: 17.440

2.  Nurses' experience of an Extracorporeal Membrane Oxygentation (ECMO) clinical support team during the COVID-19 pandemic: A service evaluation.

Authors:  Danielle Shaffi; Kimberley Driver; Emma Shaw Núñez
Journal:  Nurs Crit Care       Date:  2022-07-25       Impact factor: 2.897

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.